Alexion hikes forecast on big leap in Soliris sales; Zogenix hits back at Massachusetts restrictions on Zohydro;

@FiercePharma: Top-read special report: The top 10 pharma companies by 2013 revenue. Feature | Follow @FiercePharma

@TracyStaton: Novartis, GSK team up in consumer JV to save big money, gain big scale. More | Follow @TracyStaton

@EricPFierce: Gilead turns in eye-popping results because of huge sales of Sovaldi, $2.3B in Q1 sales for the hep C drug. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Allergan poison pill presages a battle against Valeant's $47B takeover. Story | Follow @CarlyHFierce

> Rare disease specialist Alexion Pharmaceuticals ($ALXN) hiked its full-year forecast again after its only marketed drug, Soliris, delivered a 67% increase in Q1 sales, to $567 million. Report

> After Massachusetts Gov. Deval Patrick backed away from banning its controversial new pain drug Zohydro, Zogenix ($ZGNX) balked at the restrictions Patrick chose to impose instead. Report

> GlaxoSmithKline ($GSK) set up a $500,000 endowment at the arts-oriented Barnes Foundation in Philadelphia, after selling off the art collection that once hung in its offices in that city. Report

> Merck ($MRK) tapped Catalent to make its new sublingual immunotherapies for allergies, Ragwitek and Grastek. Report

> AbbVie ($ABBV) is funding 10 scholarships for Canadian students suffering from Crohn's disease and ulcerative colitis. Report

Medical Device News

@FierceMedDev: Lombard Medical revives stateside IPO plans with a $55M debut. Article | Follow @FierceMedDev

@VarunSaxena2: BREAKING: Zimmer buying fellow orthopedics company Biomet for $13.35 billion. | Follow @VarunSaxena2

@EmilyWFierce: New genetic-bionic treatment for hearing loss could help improve pitch perception in those with cochlear implants. Article from Wired | Follow @EmilyWFierce

@MichaelGFierce: X-ray-activated nanoparticles release cancer-killing light deeper into tissue. More from FierceDrugDelivery | Follow @MichaelGFierce

> Varian's profits slip as revenue ticks up slightly. Story

> BioFire buy boosts bioMérieux earnings. Article

> Breast cancer screening company Quantason files for Chapter 11. More

Biotech News

@FierceBiotech: An international biotech tackles CRISPR gene editing tech with $25M bankroll. More | Follow @FierceBiotech

@JohnCFierce: You gotta give $AZN credit. They keep spinning. Beefing up PhIII, which should have been Soriot's initial focus. More from the FT | Follow @JohnCFierce

@DamianFierce: $CELG opens down 5%. Perhaps a $710M deal didn't thrill investors who just watched R&D costs drag profits. | Follow @DamianFierce

@EmilyMFierce: Genetically engineered mosquitoes could be vital weapon against malaria. More from The Guardian | Follow @EmilyMFierce

> Hyperion bets up to $570M on diabetes biotech Andromeda. More

> AstraZeneca continues to chop back, spotlights immuno-oncology PhIII. Report

> J&J snags FDA OK for rare blood disorder drug siltuximab. Article

Pharma Manufacturing News

> FDA is now reporting recalls still awaiting classification. News

> China's Sinovac gets $9.6M grant to build vaccine plant. Article

> Report: Industry's regulatory-centric focus for manufacturing will no longer cut it. More

> Bristol-Myers extends manufacturing pact with Samsung. Story

> Wockhardt smacked by state regulator in India. Report

> Regulatory issues crush India's drug export growth. Item

Vaccines News

> Sinovac scores $9.6M Chinese grant for new hand, foot and mouth disease vaccine. Article

> Tetanus shot stored at higher temperatures as effective as cold chain-stored jab. More

> Immune discovery puts vaccine for H. pylori closer in sight. Story

> MERS vaccine to ease outbreak within 6 months, virologist says. Item

> Novartis bids farewell to vaccines with $7.1B sale to GSK. News

> U.K. health secretary asks Novartis CEO for Bexsero price cut. Report

And Finally... More evidence for the welcome news that dark chocolate is a healthy snack. Report (sub. req.)

Suggested Articles

A suspected cancer-causing impurity that has been found in some blood pressure medicines has now shown up in Zantac and some OTC antacids.

Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.

New data shows a significant reduction in relapse rates in patients taking Novartis' repurposed cancer drug ofatumumab.